Wednesday, 27 July 2011

Biogen Idec wins European apprival for MS drug

Biogen Idec said Monday it received conditional regulatory approval in Europe to market its drug Fampyra, a treatment to improve walking in patients with multiple sclerosis, a disease in which the body attacks the brain and spinal cord.  For more click here.